{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T07:26:41Z","timestamp":1787038001401,"version":"build-2736575974"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s00228-026-04150-3","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T03:12:09Z","timestamp":1785208329000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Population pharmacokinetic modeling of amisulpride drug interactions and a transporter binding analysis"],"prefix":"10.1007","volume":"82","author":[{"given":"Tongying","family":"Gan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bixuan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,28]]},"reference":[{"issue":"2","key":"4150_CR1","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/s2215-0366(21)00395-3","volume":"9","author":"GBD 2019 Mental Disorders Collaborators","year":"2022","unstructured":"GBD 2019 Mental Disorders Collaborators (2022) Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019. lancet Psychiatry 9(2):137\u2013150. https:\/\/doi.org\/10.1016\/s2215-0366(21)00395-3","journal-title":"lancet Psychiatry"},{"issue":"12","key":"4150_CR2","doi-asserted-by":"publisher","first-page":"5319","DOI":"10.1038\/s41380-023-02138-4","volume":"28","author":"M Solmi","year":"2023","unstructured":"Solmi M, Seitidis G, Mavridis D, Correll CU, Dragioti E, Guimond S, Tuominen L, Darg\u00e9l A, Carvalho AF, Fornaro M, Maes M, Monaco F, Song M, Il Shin J, Cortese S (2023) Incidence, prevalence, and global burden of schizophrenia - data, with critical appraisal, from the global burden of disease (GBD) 2019. Mol Psychiatry 28(12):5319\u20135327. https:\/\/doi.org\/10.1038\/s41380-023-02138-4","journal-title":"Mol Psychiatry"},{"key":"4150_CR3","doi-asserted-by":"publisher","first-page":"114218","DOI":"10.1016\/j.psychres.2021.114218","volume":"305","author":"A Srivastava","year":"2021","unstructured":"Srivastava A, Dada O, Qian J, Al-Chalabi N, Fatemi AB, Gerretsen P, Graff A, De Luca V (2021) Epigenetics of schizophrenia. Psychiatry Res 305:114218. https:\/\/doi.org\/10.1016\/j.psychres.2021.114218","journal-title":"Psychiatry Res"},{"issue":"5","key":"4150_CR4","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1038\/s41380-023-01949-9","volume":"28","author":"RA McCutcheon","year":"2023","unstructured":"McCutcheon RA, Keefe RSE, McGuire PK (2023) Cognitive impairment in schizophrenia: aetiology, pathophysiology, and treatment. Mol Psychiatry 28(5):1902\u20131918. https:\/\/doi.org\/10.1038\/s41380-023-01949-9","journal-title":"Mol Psychiatry"},{"issue":"4","key":"4150_CR5","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.cmet.2023.02.015","volume":"35","author":"S Edwin Thanarajah","year":"2023","unstructured":"Edwin Thanarajah S, DiFeliceantonio AG, Albus K, Kuzmanovic B, Rigoux L, Iglesias S, Han\u00dfen R, Schlamann M, Cornely OA, Br\u00fcning JC, Tittgemeyer M, Small DM (2023) Habitual daily intake of a sweet and fatty snack modulates reward processing in humans. Cell Metabol 35(4):571\u2013584e576. https:\/\/doi.org\/10.1016\/j.cmet.2023.02.015","journal-title":"Cell Metabol"},{"key":"4150_CR6","doi-asserted-by":"publisher","unstructured":"Dionysopoulou S, Charmandari E, Bargiota A, Vlahos N, Mastorakos G, Valsamakis G (2021) The role of hypothalamic inflammation in diet-induced obesity and its association with cognitive and mood disorders. Nutrients 13(2). https:\/\/doi.org\/10.3390\/nu13020498","DOI":"10.3390\/nu13020498"},{"key":"4150_CR7","doi-asserted-by":"publisher","first-page":"769309","DOI":"10.3389\/fendo.2021.769309","volume":"12","author":"M Afzal","year":"2021","unstructured":"Afzal M, Siddiqi N, Ahmad B, Afsheen N, Aslam F, Ali A, Ayesha R, Bryant M, Holt R, Khalid H, Ishaq K, Koly KN, Rajan S, Saba J, Tirbhowan N, Zavala GA (2021) Prevalence of overweight and obesity in people with severe mental illness: Systematic review and meta-analysis. Front Endocrinol 12:769309. https:\/\/doi.org\/10.3389\/fendo.2021.769309","journal-title":"Front Endocrinol"},{"issue":"4","key":"4150_CR8","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1093\/schbul\/sbaa191","volume":"47","author":"D Siskind","year":"2021","unstructured":"Siskind D, Gallagher E, Winckel K, Hollingworth S, Kisely S, Firth J, Correll CU, Marteene W (2021) Does switching antipsychotics ameliorate weight gain in patients with severe mental illness? A systematic review and meta-analysis. Schizophr Bull 47(4):948\u2013958. https:\/\/doi.org\/10.1093\/schbul\/sbaa191","journal-title":"Schizophr Bull"},{"key":"4150_CR9","doi-asserted-by":"publisher","unstructured":"Carli M, Kolachalam S, Longoni B, Pintaudi A, Baldini M, Aringhieri S, Fasciani I, Annibale P, Maggio R, Scarselli M (2021) Atypical antipsychotics and metabolic syndrome: From molecular mechanisms to clinical differences. Pharmaceuticals (Basel Switzerland) 14(3). https:\/\/doi.org\/10.3390\/ph14030238","DOI":"10.3390\/ph14030238"},{"issue":"1","key":"4150_CR10","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/s2215-0366(19)30416-x","volume":"7","author":"T Pillinger","year":"2020","unstructured":"Pillinger T, McCutcheon RA, Vano L, Mizuno Y, Arumuham A, Hindley G, Beck K, Natesan S, Efthimiou O, Cipriani A, Howes OD (2020) Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. lancet Psychiatry 7(1):64\u201377. https:\/\/doi.org\/10.1016\/s2215-0366(19)30416-x","journal-title":"lancet Psychiatry"},{"issue":"2","key":"4150_CR11","doi-asserted-by":"publisher","first-page":"e0244944","DOI":"10.1371\/journal.pone.0244944","volume":"16","author":"M Bak","year":"2021","unstructured":"Bak M, Drukker M, Cortenraad S, Vandenberk E, Guloksuz S (2021) Antipsychotics result in more weight gain in antipsychotic naive patients than in patients after antipsychotic switch and weight gain is irrespective of psychiatric diagnosis: A meta-analysis. PLoS ONE 16(2):e0244944. https:\/\/doi.org\/10.1371\/journal.pone.0244944","journal-title":"PLoS ONE"},{"issue":"3","key":"4150_CR12","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1093\/schbul\/sbac001","volume":"48","author":"H Wu","year":"2022","unstructured":"Wu H, Siafis S, Hamza T, Schneider-Thoma J, Davis JM, Salanti G, Leucht S (2022) Antipsychotic-induced weight gain: Dose-response meta-analysis of randomized controlled trials. Schizophr Bull 48(3):643\u2013654. https:\/\/doi.org\/10.1093\/schbul\/sbac001","journal-title":"Schizophr Bull"},{"issue":"1","key":"4150_CR13","doi-asserted-by":"publisher","first-page":"168","DOI":"10.4103\/ipj.ipj_133_23","volume":"33","author":"S Asif","year":"2024","unstructured":"Asif S, Pattnaik JI, Ahmed SS, Ravan JR (2024) Amisulpride as the antipsychotic of choice in severe psychotic disorder with comorbid impaired glucose tolerance. Industrial psychiatry J 33(1):168\u2013171. https:\/\/doi.org\/10.4103\/ipj.ipj_133_23","journal-title":"Industrial psychiatry J"},{"key":"4150_CR14","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.genhosppsych.2024.06.003","volume":"90","author":"NC Hegde","year":"2024","unstructured":"Hegde NC, Mishra A, Maiti R, Mishra BR, Mohapatra D, Srinivasan A (2024) Pharmacological interventions for antipsychotic-induced weight gain in schizophrenia: A network meta-analysis. Gen Hosp Psychiatry 90:12\u201321. https:\/\/doi.org\/10.1016\/j.genhosppsych.2024.06.003","journal-title":"Gen Hosp Psychiatry"},{"key":"4150_CR15","doi-asserted-by":"publisher","unstructured":"Farache Trajano L, Hayes JF, Launders N, Davies NM, Osborn DPJ, Richards-Belle A (2025) Co-prescription of metformin and antipsychotics in severe mental illness: a UK primary care cohort study. BMJ mental health 28(1). https:\/\/doi.org\/10.1136\/bmjment-2024-301505","DOI":"10.1136\/bmjment-2024-301505"},{"key":"4150_CR16","doi-asserted-by":"publisher","first-page":"161","DOI":"10.2147\/cpaa.S234256","volume":"11","author":"GM Fox","year":"2019","unstructured":"Fox GM, Roffel AF, Hartstra J, Bussian LA, van Marle SP (2019) Metabolism and excretion of intravenous, radio-labeled amisulpride in healthy, adult volunteers. Clin pharmacology: Adv Appl 11:161\u2013169. https:\/\/doi.org\/10.2147\/cpaa.S234256","journal-title":"Clin pharmacology: Adv Appl"},{"issue":"6","key":"4150_CR17","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1208\/s12248-014-9649-9","volume":"16","author":"JN Dos Santos Pereira","year":"2014","unstructured":"Dos Santos Pereira JN, Tadjerpisheh S, Abu Abed M, Saadatmand AR, Weksler B, Romero IA, Couraud PO, Brockm\u00f6ller J, Tzvetkov MV (2014) The poorly membrane permeable antipsychotic drugs amisulpride and sulpiride are substrates of the organic cation transporters from the SLC22 family. AAPS J 16(6):1247\u20131258. https:\/\/doi.org\/10.1208\/s12248-014-9649-9","journal-title":"AAPS J"},{"key":"4150_CR18","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.1016\/j.pbb.2012.04.002","volume":"102","author":"U Schmitt","year":"2012","unstructured":"Schmitt U, Kirschbaum KM, Poller B, Kusch-Poddar M, Drewe J, Hiemke C, Gutmann H (2012) In vitro P-glycoprotein efflux inhibition by atypical antipsychotics is in vivo nicely reflected by pharmacodynamic but less by pharmacokinetic changes. Pharmacol Biochem Behav 102:2312\u20132320. https:\/\/doi.org\/10.1016\/j.pbb.2012.04.002","journal-title":"Pharmacol Biochem Behav"},{"issue":"1","key":"4150_CR19","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s12987-019-0158-1","volume":"16","author":"GN Sekhar","year":"2019","unstructured":"Sekhar GN, Fleckney AL, Boyanova ST, Rupawala H, Lo R, Wang H, Farag DB, Rahman KM, Broadstock M, Reeves S, Thomas SA (2019) Region-specific blood-brain barrier transporter changes leads to increased sensitivity to amisulpride in Alzheimer\u2019s disease. Fluids barriers CNS 16(1):38. https:\/\/doi.org\/10.1186\/s12987-019-0158-1","journal-title":"Fluids barriers CNS"},{"issue":"7","key":"4150_CR20","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1007\/s00702-005-0367-4","volume":"113","author":"U Schmitt","year":"2006","unstructured":"Schmitt U, Abou El-Ela A, Guo LJ, Glavinas H, Krajcsi P, Baron JM, Tillmann C, Hiemke C, Langguth P, H\u00e4rtter S (2006) Cyclosporine A (CsA) affects the pharmacodynamics and pharmacokinetics of the atypical antipsychotic amisulpride probably via inhibition of P-glycoprotein (P-gp). J neural transmission (Vienna Austria: 1996) 113(7):787\u2013801. https:\/\/doi.org\/10.1007\/s00702-005-0367-4","journal-title":"J neural transmission (Vienna Austria: 1996)"},{"issue":"8","key":"4150_CR21","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1211\/0022357043969","volume":"56","author":"AA El Ela","year":"2004","unstructured":"El Ela AA, H\u00e4rtter S, Schmitt U, Hiemke C, Spahn-Langguth H, Langguth P (2004) Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds\u2013implications for pharmacokinetics of selected substrates. J Pharm Pharmacol 56(8):967\u2013975. https:\/\/doi.org\/10.1211\/0022357043969","journal-title":"J Pharm Pharmacol"},{"issue":"6","key":"4150_CR22","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1007\/s00125-023-05898-4","volume":"66","author":"D T\u00fcrk","year":"2023","unstructured":"T\u00fcrk D, Scherer N, Selzer D, Dings C, Hanke N, Dallmann R, Schwab M, Timmins P, Nock V, Lehr T (2023) Significant impact of time-of-day variation on metformin pharmacokinetics. Diabetologia 66(6):1024\u20131034. https:\/\/doi.org\/10.1007\/s00125-023-05898-4","journal-title":"Diabetologia"},{"issue":"4","key":"4150_CR23","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1176\/appi.ajp.2019.19010034","volume":"177","author":"S Leucht","year":"2020","unstructured":"Leucht S, Crippa A, Siafis S, Patel MX, Orsini N, Davis JM (2020) Dose-response meta-analysis of antipsychotic drugs for acute schizophrenia. Am J Psychiatry 177(4):342\u2013353. https:\/\/doi.org\/10.1176\/appi.ajp.2019.19010034","journal-title":"Am J Psychiatry"},{"issue":"14","key":"4150_CR24","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.2165\/00003495-200161140-00014","volume":"61","author":"MP Curran","year":"2001","unstructured":"Curran MP, Perry CM (2001) Amisulpride: a review of its use in the management of schizophrenia. Drugs 61(14):2123\u20132150. https:\/\/doi.org\/10.2165\/00003495-200161140-00014","journal-title":"Drugs"},{"issue":"08","key":"4150_CR25","first-page":"601","volume":"22","author":"W Guo","year":"2022","unstructured":"Guo W, Zhang L, Wang G (2022) Expert consensus on clinicalapplication of psychiatrictherapeutic drugmonitoring in china(2022edition). J Neurosci Mental Health 22(08):601\u2013608","journal-title":"J Neurosci Mental Health"},{"issue":"7","key":"4150_CR26","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1038\/s41594-023-01017-4","volume":"30","author":"Y Suo","year":"2023","unstructured":"Suo Y, Wright NJ, Guterres H, Fedor JG, Butay KJ, Borgnia MJ, Im W, Lee SY (2023) Molecular basis of polyspecific drug and xenobiotic recognition by OCT1 and OCT2. Nat Struct Mol Biol 30(7):1001\u20131011. https:\/\/doi.org\/10.1038\/s41594-023-01017-4","journal-title":"Nat Struct Mol Biol"},{"issue":"1","key":"4150_CR27","doi-asserted-by":"publisher","first-page":"9444","DOI":"10.1038\/s41467-025-64490-z","volume":"16","author":"K Romane","year":"2025","unstructured":"Romane K, Peteani G, Mukherjee S, Kowal J, Rossi L, Hou J, Kossiakoff AA, Lemmin T, Locher KP (2025) Structural basis of drug recognition by human MATE1 transporter. Nat Commun 16(1):9444. https:\/\/doi.org\/10.1038\/s41467-025-64490-z","journal-title":"Nat Commun"},{"key":"4150_CR28","doi-asserted-by":"publisher","DOI":"10.5414\/cp204334","author":"W Liu","year":"2023","unstructured":"Liu W, Zhou J, Cao M, Zhang F, Sun X (2023) A pharmacokinetic analysis of amisulpride in adult Chinese patients with schizophrenia: Impact of creatinine clearance. Int J Clin Pharmacol Ther. https:\/\/doi.org\/10.5414\/cp204334","journal-title":"Int J Clin Pharmacol Ther"},{"key":"4150_CR29","doi-asserted-by":"publisher","first-page":"3903","DOI":"10.2147\/dddt.S327506","volume":"15","author":"S Huang","year":"2021","unstructured":"Huang S, Li L, Wang Z, Xiao T, Li X, Liu S, Zhang M, Lu H, Wen Y, Shang D (2021) Modeling and simulation for individualized therapy of amisulpride in Chinese patients with schizophrenia: Focus on interindividual variability, therapeutic reference range and the laboratory alert level. Drug design. Dev therapy 15:3903\u20133913. https:\/\/doi.org\/10.2147\/dddt.S327506","journal-title":"Dev therapy"},{"issue":"3","key":"4150_CR30","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s40262-019-00821-w","volume":"59","author":"A Glatard","year":"2020","unstructured":"Glatard A, Guidi M, Delacr\u00e9taz A, Dubath C, Grosu C, Laaboub N, von Gunten A, Conus P, Csajka C, Eap CB (2020) Amisulpride: Real-world evidence of dose adaptation and effect on prolactin concentrations and body weight gain by pharmacokinetic\/pharmacodynamic analyses. Clin Pharmacokinet 59(3):371\u2013382. https:\/\/doi.org\/10.1007\/s40262-019-00821-w","journal-title":"Clin Pharmacokinet"},{"key":"4150_CR31","doi-asserted-by":"publisher","first-page":"1215065","DOI":"10.3389\/fphar.2023.1215065","volume":"14","author":"A Li","year":"2023","unstructured":"Li A, Mak WY, Ruan T, Dong F, Zheng N, Gu M, Guo W, Zhang J, Cheng H, Ruan C, Shi Y, Zang Y, Zhu X, He Q, Xiang X, Wang G, Zhu X (2023) Population pharmacokinetics of Amisulpride in Chinese patients with schizophrenia with external validation: the impact of renal function. Front Pharmacol 14:1215065. https:\/\/doi.org\/10.3389\/fphar.2023.1215065","journal-title":"Front Pharmacol"},{"issue":"18","key":"4150_CR32","doi-asserted-by":"publisher","first-page":"3371","DOI":"10.1007\/s00213-016-4379-6","volume":"233","author":"S Reeves","year":"2016","unstructured":"Reeves S, Bertrand J, D\u2019Antonio F, McLachlan E, Nair A, Brownings S, Greaves S, Smith A, Taylor D, Howard R (2016) A population approach to characterise amisulpride pharmacokinetics in older people and Alzheimer\u2019s disease. Psychopharmacology 233(18):3371\u20133381. https:\/\/doi.org\/10.1007\/s00213-016-4379-6","journal-title":"Psychopharmacology"},{"key":"4150_CR33","doi-asserted-by":"publisher","first-page":"6345","DOI":"10.2147\/dddt.S469149","volume":"18","author":"D Yan","year":"2024","unstructured":"Yan D, Ju G, Liu X, Shao Q, Zhang Y, Wang N, Yan K (2024) External validation of the population pharmacokinetic models of amisulpride and remedial strategies for delayed or missed doses. Drug Des Devel Ther 18:6345\u20136358. https:\/\/doi.org\/10.2147\/dddt.S469149","journal-title":"Drug Des Devel Ther"},{"issue":"1","key":"4150_CR34","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13293-020-00308-5","volume":"11","author":"I Zucker","year":"2020","unstructured":"Zucker I, Prendergast BJ (2020) Sex differences in pharmacokinetics predict adverse drug reactions in women. Biology sex differences 11(1):32. https:\/\/doi.org\/10.1186\/s13293-020-00308-5","journal-title":"Biology sex differences"},{"issue":"1","key":"4150_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/hup.320","volume":"17","author":"P Rosenzweig","year":"2002","unstructured":"Rosenzweig P, Canal M, Patat A, Bergougnan L, Zieleniuk I, Bianchetti G (2002) A review of the pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy volunteers. Human Psychopharmacol 17(1):1\u201313. https:\/\/doi.org\/10.1002\/hup.320","journal-title":"Human Psychopharmacol"},{"issue":"3","key":"4150_CR36","doi-asserted-by":"publisher","first-page":"100044","DOI":"10.1016\/j.dmd.2025.100044","volume":"53","author":"A Ailabouni","year":"2025","unstructured":"Ailabouni A, Prasad B (2025) Organic cation transporters 2: Structure, regulation, functions, and clinical implications. Drug Metab Dispos 53(3):100044. https:\/\/doi.org\/10.1016\/j.dmd.2025.100044","journal-title":"Drug Metab Dispos"},{"issue":"10","key":"4150_CR37","doi-asserted-by":"publisher","first-page":"100155","DOI":"10.1016\/j.dmd.2025.100155","volume":"53","author":"A Gessner","year":"2025","unstructured":"Gessner A, Picurov\u00e1 J, Englhard L, M\u00fcller F, Fromm MF, K\u00f6nig J (2025) Putative new biomarkers for renal transporter-mediated drug-drug interactions: Characterization as substrates of organic cation transporter 2, multidrug and toxin extrusion protein 1, and other important drug transporters. Drug Metab Dispos 53(10):100155. https:\/\/doi.org\/10.1016\/j.dmd.2025.100155","journal-title":"Drug Metab Dispos"},{"issue":"19","key":"4150_CR38","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1002\/1873-3468.14943","volume":"598","author":"M Pernecker","year":"2024","unstructured":"Pernecker M, Ciarimboli G (2024) Regulation of renal organic cation transporters. FEBS Lett 598(19):2328\u20132347. https:\/\/doi.org\/10.1002\/1873-3468.14943","journal-title":"FEBS Lett"},{"key":"4150_CR39","doi-asserted-by":"publisher","unstructured":"Paglialunga S, Benrimoh N, van Haarst A (2024) Innovative approaches to optimize clinical transporter drug-drug interaction studies. Pharmaceutics 16(8). https:\/\/doi.org\/10.3390\/pharmaceutics16080992","DOI":"10.3390\/pharmaceutics16080992"},{"issue":"1","key":"4150_CR40","doi-asserted-by":"publisher","first-page":"57","DOI":"10.5599\/admet.916","volume":"9","author":"A Elezovi\u0107","year":"2021","unstructured":"Elezovi\u0107 A, Mari\u0107 A, Bi\u0161\u010devi\u0107 A, Had\u017eiabdi\u0107 J, \u0160krbo S, \u0160pirtovi\u0107-Halilovi\u0107 S, Rahi\u0107 O, Vrani\u0107 E, Elezovi\u0107 A (2021) In vitro pH dependent passive transport of ketoprofen and metformin. Admet dmpk 9(1):57\u201368. https:\/\/doi.org\/10.5599\/admet.916","journal-title":"Admet dmpk"},{"issue":"1","key":"4150_CR41","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s13346-019-00706-2","volume":"11","author":"NF Younes","year":"2021","unstructured":"Younes NF, El Assasy AEI, Makhlouf AIA (2021) Microenvironmental pH-modified Amisulpride-Labrasol matrix tablets: development, optimization and in vivo pharmacokinetic study. Drug delivery translational Res 11(1):103\u2013117. https:\/\/doi.org\/10.1007\/s13346-019-00706-2","journal-title":"Drug delivery translational Res"},{"issue":"12","key":"4150_CR42","doi-asserted-by":"publisher","first-page":"12473","DOI":"10.1021\/acs.jmedchem.5c00056","volume":"68","author":"KM Redeker","year":"2025","unstructured":"Redeker KM, Kirsch N, Boretius S, Tzvetkov M, Brockm\u00f6ller J (2025) Substrate specificity of the organic cation transporters MATE1 and MATE2K and functional overlap with OCT1 and OCT2. J Med Chem 68(12):12473\u201312492. https:\/\/doi.org\/10.1021\/acs.jmedchem.5c00056","journal-title":"J Med Chem"},{"issue":"8","key":"4150_CR43","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1007\/s40262-025-01534-z","volume":"64","author":"B Morath","year":"2025","unstructured":"Morath B, Foerster KI, Chiriac U, Zaradzki M, Hoppe-Tichy T, Schrey D, Burhenne J, Czock D, Karck M, Haefeli WE, Wicha SG (2025) Effect of amiodarone on apixaban exposure in patients after cardiac surgery-a population pharmacokinetic study. Clin Pharmacokinet 64(8):1191\u20131201. https:\/\/doi.org\/10.1007\/s40262-025-01534-z","journal-title":"Clin Pharmacokinet"},{"issue":"10202","key":"4150_CR44","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/s0140-6736(19)31135-3","volume":"394","author":"M Huhn","year":"2019","unstructured":"Huhn M, Nikolakopoulou A, Schneider-Thoma J, Krause M, Samara M, Peter N, Arndt T, B\u00e4ckers L, Rothe P, Cipriani A, Davis J, Salanti G, Leucht S (2019) Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet (London England) 394(10202):939\u2013951. https:\/\/doi.org\/10.1016\/s0140-6736(19)31135-3","journal-title":"Lancet (London England)"},{"issue":"11","key":"4150_CR45","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1080\/15563650.2025.2554950","volume":"63","author":"I Berling","year":"2025","unstructured":"Berling I, Yates C, Hoffman RS, Hatten BW, Roberts DM, Wong A, Hoegberg LCG, Lonati D, Ferrer Dufol AMA, Hayes BD, Isbister GK, Paasma R, Heyerdahl F, Mackenzie CA, Othong R, Stanton M, Smith A, Gosselin S (2025) QT interval prolongation in acute antipsychotic poisoning: systematic review and recommendations. Clin Toxicol (Phila) 63(11):810\u2013837. https:\/\/doi.org\/10.1080\/15563650.2025.2554950","journal-title":"Clin Toxicol (Phila)"},{"key":"4150_CR46","doi-asserted-by":"publisher","first-page":"204512532412554","DOI":"10.1177\/20451253241255476","volume":"14","author":"O Yu","year":"2024","unstructured":"Yu O, Lu M, Lai TKY, Hahn M, Agarwal SM, O\u2019Donoghue B, Ebdrup BH, Siskind D (2024) Metformin co-commencement at time of antipsychotic initiation for attenuation of weight gain: a systematic review and meta-analysis. Therapeutic Adv Psychopharmacol 14:20451253241255476. https:\/\/doi.org\/10.1177\/20451253241255476","journal-title":"Therapeutic Adv Psychopharmacol"},{"key":"4150_CR47","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.psychres.2016.01.031","volume":"237","author":"QJ Bo","year":"2016","unstructured":"Bo QJ, Wang ZM, Li XB, Ma X, Wang CY, de Leon J (2016) Adjunctive metformin for antipsychotic-induced hyperprolactinemia: A systematic review. Psychiatry Res 237:257\u2013263. https:\/\/doi.org\/10.1016\/j.psychres.2016.01.031","journal-title":"Psychiatry Res"},{"key":"4150_CR48","doi-asserted-by":"publisher","first-page":"892477","DOI":"10.3389\/fnmol.2022.892477","volume":"15","author":"C Zhu","year":"2022","unstructured":"Zhu C, Li R, Ju M, Xiao X, Yuan TF, Jin Z, Zhao J (2022) Metformin in the treatment of amisulpride-induced hyperprolactinemia: A clinical trial. Front Mol Neurosci 15:892477. https:\/\/doi.org\/10.3389\/fnmol.2022.892477","journal-title":"Front Mol Neurosci"},{"issue":"8","key":"4150_CR49","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.jpsychires.2005.10.003","volume":"41","author":"MJ M\u00fcller","year":"2007","unstructured":"M\u00fcller MJ, Regenbogen B, H\u00e4rtter S, Eich FX, Hiemke C (2007) Therapeutic drug monitoring for optimizing amisulpride therapy in patients with schizophrenia. J Psychiatr Res 41(8):673\u2013679. https:\/\/doi.org\/10.1016\/j.jpsychires.2005.10.003","journal-title":"J Psychiatr Res"},{"key":"4150_CR50","doi-asserted-by":"publisher","first-page":"103699","DOI":"10.1016\/j.ajp.2023.103699","volume":"87","author":"J Ding","year":"2023","unstructured":"Ding J, Yang L, Cui X, Li L, Liu J, Sun H, Wang T, Zhang Y (2023) A 5-year retrospective study of amisulpride steady-state plasma concentration in patients with schizophrenia in real-life settings based on therapeutic drug monitoring data. Asian J psychiatry 87:103699. https:\/\/doi.org\/10.1016\/j.ajp.2023.103699","journal-title":"Asian J psychiatry"},{"issue":"3","key":"4150_CR51","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1097\/ftd.0000000000000585","volume":"41","author":"AK J\u00f6nsson","year":"2019","unstructured":"J\u00f6nsson AK, Spigset O, Reis M (2019) A compilation of serum concentrations of 12 antipsychotic drugs in a therapeutic drug monitoring setting. Ther Drug Monit 41(3):348\u2013356. https:\/\/doi.org\/10.1097\/ftd.0000000000000585","journal-title":"Ther Drug Monit"},{"key":"4150_CR52","doi-asserted-by":"publisher","unstructured":"Wang ST, Li Y (2017) Development of a UPLC-MS\/MS method for routine therapeutic drug monitoring of aripiprazole, amisulpride, olanzapine, paliperidone and ziprasidone with a discussion of their therapeutic reference ranges for Chinese patients. Biomedical chromatography: BMC 31(8). https:\/\/doi.org\/10.1002\/bmc.3928","DOI":"10.1002\/bmc.3928"},{"issue":"6","key":"4150_CR53","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1111\/j.1600-0447.2009.01429.x","volume":"120","author":"A Sparshatt","year":"2009","unstructured":"Sparshatt A, Taylor D, Patel MX, Kapur S (2009) Amisulpride - dose, plasma concentration, occupancy and response: implications for therapeutic drug monitoring. Acta psychiatrica Scandinavica 120(6):416\u2013428. https:\/\/doi.org\/10.1111\/j.1600-0447.2009.01429.x","journal-title":"Acta psychiatrica Scandinavica"},{"issue":"4","key":"4150_CR54","doi-asserted-by":"publisher","first-page":"427","DOI":"10.13286\/j.1001-5213.2025.04.09","volume":"45","author":"T Gan","year":"2025","unstructured":"Gan T, Liu C, Li L, Li L (2025) A real-world study on the reference interval of plasma concentration of amisulpride for treating schizophrenia. Chin J Hosp Pharm 45(4):427\u2013432and438. https:\/\/doi.org\/10.13286\/j.1001-5213.2025.04.09","journal-title":"Chin J Hosp Pharm"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04150-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-026-04150-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04150-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T06:55:42Z","timestamp":1787036142000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-026-04150-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,28]]},"references-count":54,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["4150"],"URL":"https:\/\/doi.org\/10.1007\/s00228-026-04150-3","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,28]]},"assertion":[{"value":"12 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This retrospective chart review study involving human participants was in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The Human Investigation Committee (IRB) of the Affiliated Brain Hospital of Guangzhou Medical University approved this study (Approval Number: 2021027).","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"not applicable.","order":3,"name":"Ethics","label":"Clinical trial number","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"220"}}